Paraneoplastic cerebellar ataxia with central hypoventilation
Citation Manager Formats
Make Comment
See Comments

We describe a patient with small cell lung cancer with anti-Hu paraneoplastic cerebellar degeneration and central hypoventilation syndrome. This highlights the insidious clinical presentation of central hypoventilation and raises awareness of this condition as a paraneoplastic phenomenon. This case also highlights the complex circuitry of automatic respiration in the brainstem and the potential role of the cerebellum. We emphasize the difficulties in managing paraneoplastic central hypoventilation.
Case report.
A 52-year-old woman presented to her oncologist with complaints of fatigue and poor memory. She was a smoker and had small cell carcinoma diagnosed 13 months ago on CT chest and confirmed histologically on fine needle biopsy. PET demonstrated it was confined to the right hilum and mediastinal lymph nodes with no distant disease. She was treated with chemotherapy (cisplatin and etoposide) and concurrent radiotherapy. She had prophylactic cranial irradiation 6 months after diagnosis with no acute or early delayed side effects.
The patient presented 13 months after diagnosis with poor memory and feeling “vague.” Over the next month, the patient developed dizziness and unsteady gait. Her clinical examination revealed a broad-based ataxic gait, upbeat nystagmus, and dysdiadochokinesis. There were no other cranial nerve abnormalities. MRI brain was unremarkable. CSF demonstrated 10 leukocytes (86% lymphocytes, 14% monocytes), 146 erythrocytes, protein 1.01 g/L, and glucose 4.1 mmol/L. Anti-Hu antibodies were detected in CSF and serum. PET scan demonstrated glucose hypermetabolism in the cerebellum and in the left ovary (figure). A diagnosis of paraneoplastic cerebellar syndrome was made. The patient was treated with methylprednisolone 1 g for 5 days. A left salpingo-oophorectomy was performed and histology confirmed metastatic small cell carcinoma. Postoperatively, she was hypoxic and hypercapneic, with a PaCO2 of 70–80 mm Hg. She had apneic episodes when asleep and her ventilation improved when alert and when exercising. She was diagnosed with central hypoventilation and commenced on noninvasive ventilation. IV immunoglobulin was given for 5 days (0.4 mg/kg). Repeat serum anti-Hu antibodies were detected 1 month later. The patient was confused and agitated and unable to comply with bilevel positive airway pressure, and she was mechanically ventilated. The patient was unable to be extubated and a tracheostomy was performed. When the sedation was weaned, the patient became agitated and compromised the tracheostomy. After 4 weeks of mechanical ventilation and sedation, a decision was made with the family to de-cannulate the patient and the patient died. An autopsy was declined by the family.
(A) Bilateral cerebellar hypermetabolism. (B) Left posterior pelvis markedly glucose avid lesion.
Discussion.
This is a case of anti-Hu paraneoplastic cerebellar syndrome and central hypoventilation. Central hypoventilation can be inherited or acquired. The inherited form is seen in congenital central hypoventilation with mutations in the paired-like homeobox PHOX2B gene. Acquired central hypoventilation has been associated with brainstem tumors and ischemic lesions and Chiari malformations. Central hypoventilation has been reported in anti-Hu paraneoplastic brainstem encephalomyelitis1 and in patients later identified as having anti-NMDA encephalitis.2 To our knowledge, there are no reports of central hypoventilation after prophylactic cranial irradiation and its effects on the brainstem and cerebellum are unknown.
The mechanism of central hypoventilation is thought to be disruption of the brainstem respiratory nuclei. The nuclei identified in respiration include the dorsal respiratory group in the nucleus of tractus solitarius, the pneumotaxic center or pontine respiratory group, and the ventral respiratory group.3 The nuclei that are affected might correspond with the type of central ventilation disorder, either loss of automatic or voluntary breathing control, and could determine the therapeutic approach.3 The pathologic involvement of these brainstem regions has been demonstrated in autopsy findings of a patient with anti-Hu-associated central hypoventilation:perivenous and parenchymal inflammatory infiltrates and severe neuronal loss in the medulla involving the 12th neuronal nuclei, inferior olives, nucleus ambiguus, and reticular system.4
The role of the cerebellum in control of respiration has been demonstrated in congenital central hypoventilation syndrome, in which the cerebellar cortex and deep nuclei have decreased signaling in response to hypercapnea.5 In mouse models of sudden infant death syndrome, mutant mice with Purkinje cell loss have shown impaired compensatory breathing responsiveness to hypercapnea.6
Chronic hypoventilation can present more insidiously than acute hypoventilation with morning headache, daytime fatigue, and mental status change. Patients with central hypoventilation have normal ventilation while awake but hypoventilate when asleep. The normal response to hypercapnia with increased ventilation is diminished. An arterial blood gas analysis and polysomnography can be used to identify this condition.
Treatment of the primary tumor does not always abolish the paraneoplastic syndrome. Immune therapies have minimal efficacy on paraneoplastic conditions with intracellular antigens. Central hypoventilation can be managed with noninvasive ventilation, but requires patient compliance. Congenital central hypoventilation has been managed with noninvasive ventilation, diaphragm pacing by phrenic nerve stimulation, tracheostomy, and home ventilation. There are reports of phrenic nerve pacing for central hypoventilation from brainstem encephalitis.7
Footnotes
Author contributions: A.K. contributed to conception, design, and acquisition of data, drafting the manuscript, and revising it critically. M.H. contributed to conception and revising the article critically. M.B. and D.B. revised the article critically. All authors give final approval of the version to be submitted.
Study funding: No targeted funding.
Disclosure: A. Kunchok reports no disclosures. D. Barnes serves as an Associate Editor for Respirology and is on the editorial boards of Chest, Sleep, and Journal of Thoracic Oncology. M. Boyer served on the editorial board for Clinical Lung Cancer and received research support from Amgen, Astra Zeneca, Merck Sharpe and Dohme, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, Boehringer Ingelheim, Pfizer, and Cancer Institute NSW. M. Halmagyi serves on the scientific advisory board for Brain Foundation of Australia, received travel funding from GN Otometrics, served on the editorial boards of Acta Otolaryngologica, Otology, Neurotology, Audiology, Neuro-otology, and Italian Journal of Otolaryngology, consulted for GN Otometrics, and received research support from National Health and Medical Research Council. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors.
- Received August 4, 2016.
- Accepted in final form October 11, 2016.
- Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
- 1.↵
- Saiz A,
- Bruna J,
- Stourac P, et al
- 2.↵
- 3.↵
- Mendoza M,
- Latorre JG
- 4.↵
- Gómez-Choco MJ,
- Zarranz JJ,
- Saiz A,
- Forcadas MI,
- Graus F
- 5.↵
- Harper RM,
- Macey PM,
- Woo MA, et al
- 6.↵
- Calton MA,
- Howard JR,
- Harper RM,
- Goldowitz D,
- Mittleman G
- 7.↵
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Resident and Fellow Section
Pearls & Oy-stersReversible Ondine's curse in a case of lateral medullary infarctionMichael Mendoza, Julius Gene Latorre et al.Neurology, January 07, 2013 -
Clinical Implications of Neuroscience Research
Brainstem respiratory chemosensitivity: New insights and clinical implicationsEduardo E. Benarroch et al.Neurology, June 11, 2007 -
Articles
GABAB receptor antibodies in limbic encephalitis and anti-GAD–associated neurologic disordersA. Boronat, L. Sabater, A. Saiz et al.Neurology, February 28, 2011 -
Article
Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesFrancesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021